📈 Jumpstart Signal Watchlist — August 31, 2026

🏢 What they do: Mitek Systems, Inc. (MITK) specializes in digital identity verification, authentication, biometrics, mobile image capture, and fraud detection solutions. Its enterprise-grade platform enables secure onboarding, check deposits, transaction protection, and real-time defense against threats like deepfakes and synthetic fraud for banks, fintechs, and other organizations.
- 🎯 Current $18.46 is 8% below 3yr high $20.14 · ⏳ SMA200 $14.08 (current price $18.46 is above) · 💰 Market Cap $833M
- MITK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 240% (>20%); Revenue growth 18% (>15%); Low LT D/E 0.20 (<1.0); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 8/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 52 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Mitek Reports Fiscal Third Quarter Revenue of $54.0 Million, Up 18% Year-Over-Year; Raises Full-Year Outlook — Yahoo Finance / Business Wire.
🤖 Mitek reported Q3 fiscal 2026 results with revenue up 18% year over year and raised full-year revenue and adjusted EBITDA margin guidance. The company also highlighted record Fraud & Identity SaaS revenue and new leadership appointments, which support a constructive view on the stock.
✅ Mitek Systems (NASDAQ:MITK) Upgraded by Zacks Research to Strong-Buy Rating — MarketBeat.
🤖 Zacks Research upgraded Mitek Systems to strong-buy, adding to a generally bullish analyst tone around the name. Upgrades can support sentiment and valuation, even though the article notes the broader consensus remains mixed.
⚪️ Mitek names Aaron Seyler as chief revenue officer — Investing.com.
🤖 Mitek announced Aaron Seyler as chief revenue officer effective August 17, 2026. This is operationally relevant but does not by itself change financial results or guidance, so the stock impact is limited.
🍭 Bonus (B): 10/10 — Computer Peripheral Equipment (Technology sector)

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.46 is 12% below 3yr high $14.14 · ⏳ SMA200 $6.44 (current price $12.46 is above) · 💰 Market Cap $703M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (16.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 55 in healthy mid-range
- ⚠️ RSI reversing from overbought (55) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Paysign at 17th Annual Midwest IDEAS Conference — Investing.com.
🤖 Paysign highlighted continued growth in its plasma payments and faster-expanding patient affordability business at the conference. The company also reiterated its raised 2026 revenue and EBITDA outlook, which is supportive for the stock.
✅ Paysign (NASDAQ:PAYS) Hits New 12-Month High — MarketBeat.
🤖 This article followed Paysign’s strong Q2 earnings beat and raised guidance, while also noting multiple positive analyst targets and ratings. The new 12-month high reflects improving investor sentiment after the results.
✅ Paysign (NASDAQ:PAYS) Sets New 1-Year High — MarketBeat.
🤖 The piece says Paysign reached a fresh 1-year high amid continued buy ratings and higher price targets from analysts. It reinforces the post-earnings momentum in the shares.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $13.81 is 8% below 3yr high $14.97 · ⏳ SMA200 $9.58 (current price $13.81 is above) · 💰 Market Cap $1.3B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
- ⚠️ RSI reversing from overbought (54) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ MeiraGTx Reports Second Quarter 2026 Financial and Operational Results — Globe Newswire via Yahoo Finance.
🤖 The company reported Q2 2026 results and disclosed positive clinical and operational updates, including Breakthrough Therapy Designation and positive three-year Phase 1 AQUAx data. It also announced the bota-vec acquisition and a $100 million equity financing, which materially strengthened the balance sheet.
✅ RBC Adjusts PT on MeiraGTx to $27 From $26, Maintains Outperform Speculative Risk Rating — MT Newswires via Yahoo Finance.
🤖 RBC raised its price target and kept an Outperform-style rating, signaling improved analyst expectations for the stock. A higher target from a major broker is generally supportive for MGTX sentiment.
⚪️ MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) — Globe Newswire via Yahoo Finance.
🤖 This is a routine equity inducement grant for a new employee, which has little immediate operating impact. It is company-specific, but it is not a major catalyst for the stock.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $10.94 is 17% below 3yr high $13.11 · ⏳ SMA200 $8.38 (current price $10.94 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 9/20
- 🔔 Strong above EMA21 (10.0%)
- 🔔 Strong above EMA50 (13.9%)
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ BlackRock Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR — MarketBeat.
🤖 BlackRock disclosed a large new stake in VIR, which can be viewed as a strong institutional vote of confidence. The article also notes continued positive analyst coverage and a higher price target, both supportive for the stock.
✅ ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR — MarketBeat.
🤖 The filing highlights new institutional buying in VIR and cites a broadly constructive analyst backdrop. New share accumulation by a fund is generally favorable for sentiment around the stock.
✅ HC Wainwright reiterates Vir Biotechnology stock rating on trial progress — Investing.com.
🤖 HC Wainwright reiterated a Buy rating and $20 price target, pointing to progress in VIR’s hepatitis D programs. Analyst affirmation is usually supportive for the share price, especially when tied to clinical momentum.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $22.64 is 2% below 3yr high $23.04 · ⏳ SMA200 $15.51 (current price $22.64 is above) · 💰 Market Cap $620M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Base breakout (range: 9.7%); Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (6.2%)
- 🔔 Strong above EMA50 (10.8%)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Ooma, Inc. Announces Co-Marketing Agreement with Thryv — Business Wire.
🤖 Ooma announced a co-marketing agreement with Thryv to expand awareness of its solutions among small and medium-sized service businesses. This is positive for OOMA because it may support customer acquisition and business revenue growth.
✅ Ooma Named Top VoIP Provider by IT Professionals in 2026 Spiceworks Voice of IT Survey — Business Wire.
🤖 Ooma said it was named the top VoIP provider in a 2026 Spiceworks survey. That kind of recognition is mildly positive because it can strengthen brand credibility and support sales efforts.
✅ Ooma Reports Fiscal Second Quarter 2027 Financial Results — Yahoo Finance / Business Wire.
🤖 Ooma reported Q2 revenue of $83.2 million, up 25% year over year, and adjusted EBITDA of $12.4 million, while non-GAAP EPS came in at $0.35. The strong beat and profitability improvements are positive for the stock.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $52.39 is 6% below 3yr high $55.72 · ⏳ SMA200 $39.70 (current price $52.39 is above) · 💰 Market Cap $2.7B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 52 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons B stock hits 52-week high at 54.49 USD — Investing.com.
🤖 The article says WLYB reached a 52-week high and highlights a strong 1-year gain, which signals favorable investor momentum for the stock.
🍭 Bonus (B): 0/10 — Book Publishing

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $57.09 is 3% below 3yr high $58.89 · ⏳ SMA200 $43.74 (current price $57.09 is above) · 💰 Market Cap $1.2B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ ScanSource Delivers Strong Fourth Quarter and Full-Year Results — Business Wire.
🤖 ScanSource reported fourth-quarter net sales of $953.1 million, up 17.3% year over year, and fiscal 2026 net sales of $3.23 billion. The strong revenue growth suggests improving demand and is supportive for the stock.
✅ ScanSource to Acquire MicroAge, a Leading IT Solutions Integrator — Yahoo Finance / Business Wire.
🤖 ScanSource announced a $220.5 million all-cash agreement to acquire MicroAge, which it says will expand growth technologies, services capabilities, and addressable market. Investors may view the deal as strategic growth-oriented expansion, although it adds execution risk.
✅ ScanSource shares jump 19% after Q4 beat and $220.5 million MicroAge deal — Yahoo Finance.
🤖 The article says shares surged after ScanSource beat earnings and revenue expectations and announced the MicroAge acquisition. Better-than-expected quarterly performance and a strategic deal are both positive catalysts for the stock.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $34.56 is 60% below 3yr high $85.47 · ⏳ SMA200 $20.98 (current price $34.56 is above) · 💰 Market Cap $2.6B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.7%)
- 🔔 Strong above EMA50 (21.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Five9 stock hits 52-week high at 34.61 USD — Investing.com.
🤖 Five9 reached a new 52-week high after the company’s strong second-quarter results continued to support investor sentiment. The article links the stock’s surge to better-than-expected earnings, revenue growth, and AI revenue momentum.
✅ Five9 (NASDAQ:FIVN) Price Target Raised to $39.00 at Canaccord Genuity Group — MarketBeat.
🤖 Canaccord Genuity lifted its price target on Five9 and kept a buy rating, signaling increased analyst confidence in the stock’s outlook. The article reflects broader bullish sentiment from analysts after the company’s earnings beat.
✅ Five9’s (NASDAQ:FIVN) Q2 CY2026 Sales Beat Estimates, Quarterly Revenue Guidance Slightly Exceeds Expectations — Yahoo Finance.
🤖 Five9 posted revenue and adjusted EPS above consensus, and its next-quarter revenue guidance also came in slightly ahead of expectations. That combination is supportive for the stock because it suggests both execution and near-term outlook are improving.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Interface Inc. (TILE) is a global manufacturer of modular commercial flooring, specializing in carpet tiles, luxury vinyl tile (LVT), resilient flooring, and nora® rubber flooring.
- 🎯 Current $37.92 is 4% below 3yr high $39.32 · ⏳ SMA200 $30.44 (current price $37.92 is above) · 💰 Market Cap $2.2B
- TILE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 60% (>20%); ROE 21% (>15%); Low LT D/E 0.30 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (55) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Interface Inc (TILE) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 Interface reported Q2 2026 net sales growth and beat expectations, with management also raising guidance. That combination of stronger-than-expected results and improved outlook is favorable for TILE.
✅ Interface Introduces Between the Notes™ Carpet Tile Collection — Yahoo Finance.
🤖 This product launch adds to Interface’s commercial flooring lineup and highlights ongoing innovation. New product introductions can support future sales momentum and are generally positive for the stock.
🤖 The company declared a routine $0.03 quarterly dividend. This is a shareholder-return update, but it does not materially change the operating outlook.
⚪️ Interface Highlights Investor Engagement at Midwest IDEAS Conference — Investing.com.
🤖 The conference appearance mainly reiterated Interface’s premium-growth and sustainability strategy rather than delivering a major new financial catalyst. It is informative, but the direct stock impact appears limited.
🍭 Bonus (B): 0/10 — Textile Mill Products